Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cost of Revenue for 5 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 26.8% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.5 million, a 45.81% increase, with the full-year FY2025 number at $19.5 million, up 45.81% from a year prior.
  • Cost of Revenue was $4.8 million for Q4 2025 at Rhythm Pharmaceuticals, down from $5.5 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $5.5 million in Q2 2025 to a low of $4000.0 in Q1 2021.
  • A 5-year average of $2.2 million and a median of $2.3 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 5650.0% in 2022, then increased 17.14% in 2024.
  • Rhythm Pharmaceuticals' Cost of Revenue stood at $236000.0 in 2021, then surged by 335.59% to $1.0 million in 2022, then soared by 214.49% to $3.2 million in 2023, then grew by 17.14% to $3.8 million in 2024, then increased by 26.8% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Cost of Revenue are $4.8 million (Q4 2025), $5.5 million (Q3 2025), and $5.5 million (Q2 2025).